News

ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.

Iambic widens the discovery search, but AbbVie disclosed no targets, payment amounts or development timetable.

Eli Lilly (LLY) grew revenue 49.6% over the last twelve months, the fastest of the six companies in its peer group. It also runs the group's widest operating margin, at 49.7%. Yet its 53.4% stock return ranks only third, behind Merck and Johnson & Johnson, which both grew far more slowly. The open question is how long Mounjaro and Zepbound can carry a lead the stock has not matched.

Oruka Therapeutics' (ORKA) lead program of long-acting IL-23 in moderate-to-severe psoriasis maintai

AbbVie and Pfizer are reshaping their growth strategies as new drugs, acquisitions, pipelines and patent challenges shape their outlooks.

ABBV is expanding its oncology pipeline with newer therapies and diverse approaches to offset Imbruvica's decline.

It would be hard for investors to replicate the company's return over the past decade.

AI drug discovery is about to get a public-market test with unusually recognizable backers. Iambic Therapeutics filed for a U.S. IPO on September 21 after raising money from NVIDIA Corporation (NASDAQ:NVDA) and Qatar Investment Authority, and the same day announced a multi-year research collaboration with AbbVie Inc. (NYSE:ABBV). Iambic will use its AI platform to […]

AbbVie's management has changed what it puts first on its earnings calls. One growth figure used to open the script. Management last mentioned that figure in the fiscal fourth quarter 2025 call. AbbVie (ABBV) never said it would stop reporting it. So which figure was it, and why did it matter.

Pfizer's COVID products keep shrinking. The company's total revenue has been flat for a year. That makes the best case for this stock easy to miss. It does not rest on the medicines you already know Pfizer (PFE) for. It is not another round of cost cuts either. It rests on a smaller and faster part of the company. So where is that growth coming from.

AbbVie (NYSE:ABBV) received European Commission approval for RINVOQ in polyarticular juvenile idiopathic arthritis for patients as young as two. Allergan Aesthetics launched AA Signature SKIN360 in the U.S., offering a multimodal digital platform for medical aesthetics consultations. AbbVie entered AI-focused collaborations with Iambic and the AISB Bind project to use advanced models in drug discovery and molecular binding prediction. The RINVOQ pediatric extension, AA Signature SKIN360...

Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.

Merck (MRK) stock gained about 89% in the year from mid-September 2025, against a 17.1% price gain for the S&P 500. It also beat Johnson & Johnson (JNJ), up 58%, and Eli Lilly (LLY), up 54%. The signs were public long before the run, in what management kept saying about its drug pipeline. The reported sales told a different story.

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers.

AbbVie (NYSE:ABBV) announced on Tuesday that the European Commission has approved Rinvoq (upadacitinib) for the treatment of active polyarticular juvenile idiopathic arthritis. The approval covers children aged two years and older who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).

Replacing a top-tier salary with dividends sounds like a portfolio problem, but the yield you chase could cost you far more than the shares you buy. The answer depends on a tradeoff most investors never think to run.

Novo Nordisk's (NVO) US-listed shares declined as the Danish drugmaker unveiled its long-term growth

Pfizer (PFE) has returned 23.1% over the past year and trades about 5% below its three-year high. Yet one question keeps coming back on its earnings calls: would it ever cut the dividend? An analyst asked it outright on the August call, and another tied it to a big acquisition in May. So what would a cut take, and what would it change.

AbbVie (NYSE:ABBV) shared new real-world and pediatric safety data for VRAYLAR in MDD and bipolar I at Psych Congress 2026. The findings covered routine clinical practice settings, including patients with complex comorbidities and underserved groups. Pediatric data for VRAYLAR added information on safety and use in younger patients with mood disorders. The fresh VRAYLAR real-world and pediatric results sit against a wider backdrop our research has uncovered. Check out 4 warning signs that...

Eli Lilly (LLY) trades near $1,150, up about 52% over the past year, and is now worth more than a trillion dollars. At that size the easy read is that the big money has been made. But Lilly has barely started selling Foundayo, its oral obesity medicine, outside the United States. So how much is left? The scenario below starts from Lilly's own trailing numbers, but the growth, margin, and multiple it assumes are ours. It is not a forecast and not a price target.

Johnson & Johnson (JNJ) stock has returned about 57% over the past year, against about 17% for the S&P 500. On the earnings it has already banked, that price looks expensive. But those earnings carry STELARA, which is losing share to biosimilar competition. What looks dear on earnings already reported comes down sharply on the earnings analysts expect.

Merck (MRK) stock returned about 87% over the past twelve months, climbing from roughly $79 to about $147. Nothing in the year's results looks like that. The medicines Merck sells today grew at their usual pace. Investors spent the year repricing what comes next.

AbbVie Inc. (NYSE:ABBV) has declared another quarterly dividend of $1.73 per share. The dividend will be paid on November 16, 2026, to shareholders of record as of October 15. There is no new increase this time, since AbbVie has kept its quarterly dividend at $1.73 throughout 2026. Still, the latest declaration confirms the higher payout […]

A biopharma giant, a chip maker, a delivery network, a trash hauler, and an oncology powerhouse walk into the same portfolio for one reason, and it has nothing to do with chasing the highest yield.

The capital required to replace a professional salary with investment income swings by more than $2 million depending on one decision, and most investors default to the wrong tier without realizing it.

Key Stats for AbbVie StockCurrent Price: $263. 04Target Price (Mid): ~$361Street Target: ~$279Potential Total Return: ~37% (over ~4.

AbbVie (ABBV) is trading within about one percent of its 52-week high after gaining roughly 24% over the past year, well ahead of the S&P 500. That price rests on two drugs, SKYRIZI above all, growing faster than 20% year over year while the company's older medicines shrink. The biggest risk to the stock makes no noise. It is the chance that this engine slows while the price assumes it cannot.

AbbVie has delivered a powerful run over the past several years, and the current share price of US$262.51 reflects significant confidence in its ability to keep turning today’s drug portfolio and pipeline into future cash. The open question for you as an investor is whether those cash flows, when you project and discount them, line up with where the stock now trades. AbbVie has returned 196.4% over the past 5 years, which raises the stakes on whether its future cash generation fully supports...

Pfizer (PFE) trades at about 95% of its 52-week high. The business that has to justify that price, the medicines it has launched and acquired, is still only about a fifth of the company. The stock returned roughly 24% over the past year against about 17% for the S&P 500, so investors have so far given the handoff the benefit of the doubt. It is a large bet on a small slice.

Johnson & Johnson (JNJ) has been a rewarding stock to hold, up about 53% over the past year against about 17% for the S&P 500. The change worth noticing over that stretch is quieter than the price. Management said sales still rose 5.6% despite a STELARA drag of about 460 basis points. Management is encouraging investors to evaluate the company's underlying momentum by presenting growth rates that exclude STELARA alongside its reported figures.